TKM PLK1

Drug Profile

TKM PLK1

Alternative Names: PLK-1SNALP; PLK1-LNP; TKM-080301; TKM-PLK1

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals; Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Polo-like kinase 1 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Suspended Adrenocortical carcinoma; Hepatocellular carcinoma; Lymphoma; Neuroendocrine tumours; Solid tumours

Most Recent Events

  • 21 Mar 2017 Suspended - Phase-I for Lymphoma (Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)
  • 21 Mar 2017 Suspended - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)
  • 21 Mar 2017 Suspended - Phase-I/II for Adrenocortical carcinoma (Second-line therapy or greater) in USA (IV) due to company focusing its efforts on its HBV assets (Arbutus 10-K filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top